RA’ANANA, Israel, April 6, 2022 /PRNewswire/ — Inspira Technologies OXY BHN Ltd. (Nasdaq: IINN, IINNW) (“Inspira” or the “Company”) today announced that it has entered into a summary distribution agreement with Bepex Ltd. (established in 1969) (“Bepex”) which includes the potential future deployment of Inspira’s ART (Augmented Respiration Technology) systems, designed to avoid the need for invasive mechanical ventilation. Bepex, one of Israel’s leading medical technology companies, imports, markets and services medical equipment for global medical device companies such as Hamilton (mechanical ventilators) and LivaNova (ECMO-Extracorporeal Membrane Oxygenation systems). As part of the collaboration with Bepex, the first systems should be deployed in the largest medical centers in Israel.
Inspira’s sketchy distribution agreement with Bepex should be followed by a more comprehensive agreement. To date, this latest sketchy deal follows three prior sketchy distribution deals previously signed by Inspira, which jointly target approximately $386 million in the US and European markets, all subject to regulatory approvals. The agreement with Bepex has an initial term of seven years, subject to the completion of product development and relevant regulatory approvals.
“We believe Inspira’s ART system is exactly what Israeli medical teams are looking for,” commented Rami Pais, CEO of Bepex. “We strongly support this breakthrough technology development, which we believe is destined to become a new category of care for the acute respiratory failure market.”
Yigal Kassif, MD. The President of the Israeli ECMO Society and Cardiac Surgeon at Sheba Medical Center said: “To date, the only known treatment available to patients after non-invasive ventilation is highly invasive mechanical ventilation, which has high risks and complications. for patients. The ART system may be an opportunity to treat patients with new technologies. Personally, I’m proud of the fact that ART was developed in Israel.”
Disclaimer of Forward-Looking Statements
This press release contains express or implied forward-looking statements pursuant to United States federal securities laws. For example, the Company uses forward-looking statements when discussing the terms of the summary distribution agreement with Bepex, potential target amounts that may be derived under the summary distribution agreements signed to date, that the ART system is intended to become a new category of care for the acute respiratory failure market, that the ART system may be an opportunity to treat patients with new technology and potential regulatory approvals for the sale and commercialization of ART systems in the jurisdictions concerned. These forward-looking statements and their implications are based solely on the current expectations of the Company’s management and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. . Except as otherwise required by law, the Company undertakes no obligation to issue revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unforeseen events. More detailed information about the risks and uncertainties affecting the Company can be found under the heading “Risk Factors” in the Company’s Annual Report on Form 20-F for the year ended. the 31st of December2021 filed with the SEC, which is available on the SEC’s website, www.sec.gov
Contact with Investor Relations:
Miri Segal, MS-IR LLC+917-607-8654
[email protected], [email protected]